How Ascendis Pharma A/S stacks up

ASND · against 588 other Healthcare companies listed in US-listed

Valuation

36/ 100

Above the middle of the pack.

Ranked #250 of 589 · scores higher than 57% of peers

Bars: peers in each 10-point band of the valuation score

75 peers with a valuation score of 30–39, including ASND · Click a bar to see the companies

Why valuation scores 36?

Weighted metrics compared with all Healthcare companies.

Mainly because of its EBITDA yield, which is weaker than most Healthcare peers.

less operating profit (EBITDA) for the company's total value: weaker than 62% of peers. EBITDA yield: 1.8% vs peer median 4.0%
more free cash flow for the price paid: stronger than 62% of peers. Free cash flow yield: 2.3% vs peer median 0.0%
Negative (a loss or cash outflow), so it counts as zero whatever the share price. Earnings yield: -1.7% vs peer median 1.5%

Metric by metric

Position: dot = ASND, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.

Metric	ASND	Peer median	Better than	Position among peers	Weight
Earnings yieldHigher is better · 577 reported	5.2%	-4.3%	90%		30%
EBITDA yieldHigher is better · 578 reported	1.8%	-0.8%	57%		50%
Free cash flow yieldHigher is better · 553 reported	2.3%	-2.3%	66%		20%
Book yieldHigher is better · 587 reported	Not reported	25.9%	—	—	Context only

A metric that is not reported is left out of the score; the other weights are rescaled.

Ranking by valuation score

Top 5 and the companies ranked around ASND

Rank	Company	Market cap	Valuation	Overall
1	Clinuvel Pharmaceuticals LimitedCUVL · US-listed	256M USD	98	80
2	Arbutus Biopharma CorporationABUS · US-listed	595M USD	96	97
2	CorMedix Inc.CRMD · US-listed	433M USD	96	81
2	Community Health Systems, Inc.CYH · US-listed	289M USD	96	57
2	InMode Ltd.INMD · US-listed	810M USD	96	69
⋯
245	Bruker CorporationBRKR · US-listed	8.6B USD	37	30
245	InnovAge Holding Corp.INNV · US-listed	1.2B USD	37	49
245	Repligen CorporationRGEN · US-listed	10.1B USD	37	61
245	Warby Parker Inc.WRBY · US-listed	2.7B USD	37	44
250	Ascendis Pharma A/SASND · US-listed	16.5B USD	36	37
250	Alphatec Holdings, Inc.ATEC · US-listed	1.2B USD	36	36
250	AtriCure, Inc.ATRC · US-listed	3.1B USD	36	53
250	Xeris Biopharma Holdings, Inc.XERS · US-listed	1.9B USD	36	47
254	Adicet Bio, Inc.ACET · US-listed	30M USD	33

Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score

Bringing the fundamentals into focus…